ADCETRIS 50 mg powder for concentrate for solution for infusion 50 mg Powder for concentrate for solution for infusion Vial

For detailed product information, please refer to official sources such as , , or , in addition to the manufacturer's official website.

ADCETRIS 50 mg Powder for Concentrate for Solution for Infusion

ADCETRIS (Brentuximab vedotin) is an advanced antibody-drug conjugate (ADC) specifically designed for the targeted treatment of certain lymphatic cancers. This medication is provided as a sterile powder for concentrate, intended to be reconstituted and diluted for intravenous infusion. It plays a crucial role in oncology by selectively delivering an anti-cancer agent directly to cells that express the CD30 marker, a protein often found on the surface of Hodgkin lymphoma cells and some types of peripheral T-cell lymphoma.

Benefits of Use:

• Targeted therapy minimizes damage to healthy cells, potentially reducing systemic side effects compared to traditional chemotherapy.
• Effective in treating relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL).
• Approved for consolidation treatment in high-risk Hodgkin lymphoma patients after autologous stem-cell transplant.
• Also indicated for certain types of peripheral T-cell lymphoma (PTCL) that express CD30.

How to Use:

1. ADCETRIS must be prepared and administered by a healthcare professional experienced in the use of antineoplastic agents.
2. The recommended dose and schedule vary depending on the specific indication and patient’s condition.
3. It is administered as an intravenous infusion over 30 minutes.
4. Patients will be monitored closely during and after the infusion for any potential reactions.
5. Always follow the specific instructions provided by your prescribing physician and the detailed product information leaflet.

Caution & Warnings:

• Peripheral neuropathy is a common and potentially severe side effect; patients should report any tingling, numbness, or pain in hands or feet.
• Neutropenia (low white blood cell count) can occur and may increase the risk of infection; regular blood counts are essential.
• Serious infections, including opportunistic infections, have been reported.
• Hepatotoxicity (liver damage) can occur; liver function tests should be monitored.
• Progressive Multifocal Leukoencephalopathy (PML), a rare but serious brain infection, has been reported.
• Tumor lysis syndrome may occur, especially in patients with rapidly proliferating tumors and high tumor burden.
• ADCETRIS should not be administered concomitantly with bleomycin due to increased pulmonary toxicity risk.
• This medication is for prescription use only and should be handled with care as per standard cytotoxic drug procedures.

Ingredients:

Active Ingredient: Brentuximab vedotin 50 mg.
Excipients: Sodium citrate dihydrate, citric acid monohydrate, trehalose dihydrate, and polysorbate 80.

Product Details:

Form: Powder for concentrate for solution for infusion.
Strength: 50 mg per vial.
Package Type: Single-use vial.
Storage: Store unopened vials in a refrigerator (2°C - 8°C). Do not freeze. Keep in the original carton to protect from light.
Manufacturer: Takeda Pharmaceutical Company Limited.